POINT Biopharma Global Inc. , a company engaged in the discovery, development, and global access to life-changing radiopharmaceuticals, recently announced the first patient in the European Union (EU) has been dosed in the Phase 3 SPLASH trial . The SPLASH trial is investigating the use of 177Lu-PNT2002, a PSMA-targeted radioligand, in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC), with entry criteria including a positive PSMA-PET scan with either 68Ga-PSMA-11 or 18F-DCFPyL.

The SPLASH trial began randomization in North America in September 2021, and a total of 37 trial sites across North America and Europe are currently enrolling patients. Site activations in remaining jurisdictions continue to further accelerate trial recruitment. The Company expects to report top-line data from SPLASH mid-2023.

To read more please visit:

First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Tri-al

Source: POINT